Form 4: Nuvalent CSO Executes Pre-Planned Option Exercises & Sales

Nuvalent's Chief Scientific Officer, Henry E. Pelish, executed pre-planned option exercises and subsequent sales of Class A Common Stock totaling 10,070 shares.

Summary

• Henry E. Pelish, Chief Scientific Officer of Nuvalent, Inc. (NUVL), reported transactions involving Class A Common Stock on October 13, 2025, and October 14, 2025.
• All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Pelish on November 1, 2024.
• On October 13, 2025, Mr. Pelish acquired a total of 7,637 shares of Class A Common Stock through the exercise of stock options at prices ranging from $18.93 to $72.35 per share.
• Concurrently on October 13, 2025, Mr. Pelish disposed of 7,637 shares of Class A Common Stock at a weighted average price of $89.81 per share.
• On October 14, 2025, Mr. Pelish acquired a total of 2,433 shares of Class A Common Stock through the exercise of stock options at prices ranging from $18.93 to $29.33 per share.
• Concurrently on October 14, 2025, Mr. Pelish disposed of a total of 2,433 shares of Class A Common Stock in multiple transactions at weighted average prices ranging from $84.98 to $87.39 per share.
• The total number of shares acquired through option exercises (10,070 shares) precisely matched the total number of shares disposed of through sales (10,070 shares) across both days.
• Following these transactions, Mr. Pelish's direct beneficial ownership of Class A Common Stock remained at 65,963 shares, indicating a net zero change in direct holdings from these specific transactions.

Sentiment

Score: 5

Explanation: The transactions are routine, pre-planned exercises of options and subsequent sales under a Rule 10b5-1 plan. This indicates financial management rather than a discretionary signal of confidence or lack thereof, leading to a neutral sentiment.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and non-discretionary approach to insider stock management.
• The exercise of stock options suggests that the Chief Scientific Officer sees value in the company's stock at the exercise prices.

Negatives

• The sale of shares by a Chief Scientific Officer, even if pre-planned, could be perceived by some investors as a lack of confidence, although the 10b5-1 plan mitigates this interpretation.

Risks

• No specific risks to the company's operations or financial health are mentioned in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future financial performance or strategic direction.

Industry Context

Insider transactions, particularly those executed under Rule 10b5-1 plans, are a common practice for corporate executives to manage their equity holdings in a pre-arranged and compliant manner. These transactions are generally viewed as routine and less indicative of management's sentiment about the company's immediate prospects compared to discretionary, unscheduled sales.

Stakeholder Impact

• Shareholders: May note the insider selling, but the pre-planned nature under a 10b5-1 plan typically mitigates concerns about management's confidence in the company's future.

Key Dates

Recommendation

The filing details pre-planned insider transactions (option exercises and subsequent sales) under a Rule 10b5-1 plan. These are routine financial management activities and do not typically signal a change in the company's fundamental outlook or warrant a strong buy/sell recommendation. The net effect on direct beneficial ownership from these transactions was zero. Therefore, a 'hold' recommendation is appropriate as this filing provides no new material information to alter an existing investment thesis.

Keywords

Nuvalent, NUVL, Insider Trading, Form 4, Stock Options, Share Sale, 10b5-1 Plan, Chief Scientific Officer, Henry Pelish, Equity Transactions